奥美拉唑联合生长抑素治疗肝硬化消化道出血的临床疗效

The Clinical Effect of Octreotide Combined with Somatostatin in the Treatment of Patients with Cirrhosis and Hemorrhage of Digestive Tract

目的:观察和分析对肝硬化消化道出血患者采用奥美拉唑和生长抑素联合进行治疗的临床疗效,旨在为临床治疗提供依据。方法:选取笔者所在医院2012年12月-2014年12月收治的肝硬化消化道出血患者80例作为临床研究对象,使用随机数字列表法将其随机分成研究组(n=40)和对照组(n=40)。对照组患者单纯给予奥美拉唑进行治疗,研究组患者在对照组的治疗基础上加用生长抑素联合进行治疗。观察两组患者的治疗效果和不良反应发生率,并进行对比分析。结果:研究组患者的总有效率(95.0%)明显高于对照组(75.0%);研究组患者的平均住院时间为(17.14±4.33)d,明显短于对照组的(26.47±5.01)d;研究组患者的再出血发生率(10.0%)明显低于对照组(32.5%),两组比较差异均有统计学意义(P<0.05)。结论:对肝硬化消化道出血患者采用奥美拉唑和生长抑素联合进行治疗具有良好的临床疗效,值得在临床上进一步推广。

Objective： To observe and analyze the clinical effect of Omeprazole and Somatostatin in the treatment of patients with cirrhosis and hemorrhage of digestive, and to provide the basis for clinical treatment.Method： 80 cases of patients with cirrhosis and hemorrhage of digestive were selected as a clinical study from December 2012 to December 2014 in our hospital, which were randomly divided into the study group（n=40） and the control group（n=40） using random number table method.The control group was treated with Omeprazole, and the study group was treated with Somatostatin on the base of the treatment of the control group.The effect of the treatment and the incidence of adverse reactions were observed and compared in the two groups.Result： The total effective rate of the study group（95.0%） was significantly higher than the control group（75.0%）; The hospitalization time of the study group was （17.14 ± 4.33）d, significantly lower than the control group of （26.47 ±5.01）d; the incidence of rebleeding in the study group（10.0%） was significantly lower than that in the control group（32.5%）, the differences were statistically significant（P〈0.05）.Conclusion： The treatment of the patients with liver cirrhosis combined with Omeprazole and Somatostatin has a good clinical effect, and it is worth to be further popularized in clinic.